Home › Smoking Reduction › NCT05703672
Switching to E-cigarettes in Smokers Not Interested in Quitting
4th Generation E-cigarettes: Reducing Harm and Quitting Combustible Cigarettes in Dual Users
Who can join
Ages 21 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * ≥ 21 years of age * Smoke \>5 cigarettes per day * Smoked cigarettes for \> 6 months * Verified smoker (CO \> 5 ppm) * Functioning telephone * Interested in switching to EC * Willing to take varenicline and complete all study visits Exclusion Criteria: * Interested in quitting smoking * Use of smoking cessation pharmacotherapy in the month prior to enrollment * Use of other tobacco products in past 30 days (i.e., cigarillos, cigars, hookah, smokeless tobacco, pipes) * EC use on \> 4 of the past 30 days * Uncontrolled hypertension: BP \> 180 (systolic) or \> 105 (diastolic) * Heart-related event in the past 30 days * Medical contraindications to VAR: unstable cardiac condition (e.g., unstable angina or AMI) cardiac event, or stroke in the past 4 weeks; renal impairment; history of clinically significant allergic reactions; history of epilepsy or seizure disorder; hospitalized for psychiatric issue in past 30 days; active suicidal ideation * Pregnant, contemplating getting pregnant, or breastfeeding * Plans to move from Kansas City metro area during the treatment and follow-up phase * Another household member enrolled in the study
About the study
The objectives of this application are to 1) compare short- and long-term harm reduction and abuse liability potential of a nicotine salt pod-based electronic cigarettes (EC) in adult (AA) exclusive EC, dual cig-EC, and exclusive cig users, 2) characterize factors that predict who switches fully, partially, or not at all, and 3) examine if harm reduction can be further enhanced by treating dual users with varenicline (VAR) to eliminate cigarette smoking.
What is being tested
- Varenicline Tartrate (drug)
- Placebo (drug)
- Electronic cigarette (other)
Sponsor: University of Kansas Medical Center · Participants: 500 · Started: Jul 17, 2023
Contact the study team
- Tricia Snow, MPH · Phone: 816-398-8960
Official record on ClinicalTrials.gov — NCT05703672
Locations in the U.S.
| Missouri | Swope Health Central, Kansas City University of Kansas Medical Center, Kansas City |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.